Fidelity Investments’s TScan Therapeutics TCRX Stock Holding History

Fidelity Investments’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.31K	Buy	1,300 +800	+160%	+$855	﹤0.01%	5082
2025 Q4	$500	Sell	500 -9,493	-95%	-$13.7K	﹤0.01%	5155
2025 Q3	$18.2K	Sell	9,993 -885	-8%	-$1.57K	﹤0.01%	4390
2025 Q2	$15.8K	Sell	10,878 -11,000	-50%	-$15.9K	﹤0.01%	4372
2025 Q1	$30.2K	Buy	21,878 +20,428	+1,409%	+$44.2K	﹤0.01%	4074
2024 Q4	$4.41K	Buy	1,450 +1,025	+241%	+$4.65K	﹤0.01%	4689
2024 Q3	$2.12K	Buy	+425	New	+$2.56K	﹤0.01%	4802

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Fidelity Investments's TCRX Position: Q1 2026 in Review

Fidelity Investments increased its TScan Therapeutics (TCRX) stake by 160% in Q1 2026, buying an estimated $855 and bringing the position to 1,300 shares worth $1.31K. The position accounts for ﹤0.01% of the portfolio, ranked #5082.

Fidelity Investments first reported a position in TCRX in Q3 2024 and has held it in 7 quarters since. The position peaked at $30.2K in Q1 2025. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

Fidelity Investments held 1,300 shares of TScan Therapeutics worth $1.31K as of Q1 2026.
Fidelity Investments bought 800 TScan Therapeutics shares in Q1 2026, an estimated $855.
TScan Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #5082 holding.
Fidelity Investments first reported a position in TScan Therapeutics in Q3 2024 and has held it in 7 quarters since.
Fidelity Investments's TScan Therapeutics position peaked at $30.2K in Q1 2025.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.